GV, Alphabet Inc's venture capital arm, led a US$58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.
The company said it will only develop treatments that involve editing adult cells, so the effects of genetic manipulation cannot be passed on to future generations.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Brazil cosmetics company Natura to invest US$5m in new brands through venture capital funds[SAO PAULO] Brazil cosmetics company Natura intends to invest up to US$5 million in new brands in beauty and wellness segments in Europe and the United States through venture capital funds, executives said on Friday. Read more at The Business Times.
ソース: BusinessTimes - 🏆 15. / 51 続きを読む »
More funds to help companies train workers, raise wages
ソース: TODAYonline - 🏆 1. / 99 続きを読む »
More funding for companies that work with unions to prepare workers for transformation: DPM HengSINGAPORE - Technological advancements should help workers do their jobs better, not replace them, said Deputy Prime Minister Heng Swee Keat on Wednesday (May 1).. Read more at straitstimes.com.
ソース: The Straits Times - 🏆 8. / 63 続きを読む »